Weight loss drug Ozempic and type 2 diabetes jabs could be used to tackle binge drinking
Doctors and NHS England’s chief warned this week demand for weight-loss jabs could overwhelm the health services
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Weight loss and type 2 diabetes jabs could benefit people with alcohol abuse problems, according to a new study.
Researchers found the common drugs led to a 50 per cent lower rate of alcohol intoxication in people taking them compared to people not prescribed them.
Their study, published in the journal Addiction, also found that off-label use of the drugs could also help people addicted to opioids.
The researchers looked at glucose-dependent insulinotropic polypeptide (GIP) drugs, which they said include brand name Mounjaro, and/or glucagon-like peptide-1 receptor agonists (GLP-1 RA), which they said included the drug Ozempic.
Health experts have suggested these drugs may curb addictions because they work on appetite but also parts of the brain which help maintain addictive behaviour.
The study comes following numerous trials claiming health benefits linked to weight loss and type 2 diabetes drugs, including improved cardiac outcomes and longer life expectancy.
This week health secretary Wes Streeting said weight-loss jabs could be given to those who are unemployed due to obesity problems as the government announced £279m investment into the UK’s life sciences sector to trial weight-loss jabs, and assess the impact on worklessness.
The latest study, led by Loyola University Chicago in the US, experts looked at 503,747 people with a history of opioid use disorder, of which 8,103 had a prescription for a GLP-1 RA or GIP.
The study found that people with the disorder who had a GLP-1 RA or GIP prescription had a 40 per cent lower rate of opioid overdose compared with those who did not have a prescription.
The study also looked at 817,309 people with a history of alcohol use disorder, of which 5,621 had a prescription for a GLP-1 RA or GIP.
It found that people with alcohol use disorder who had a GLP-1 RA or GIP prescription had a 50 per cent lower rate of alcohol intoxication compared with those who did not have a prescription.
The authors said their results showed that the drugs “should be investigated as a novel pharmacotherapy treatment option” for people with alcohol and opioid addiction.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments